
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. maintains a robust position in the biopharmaceutical sector, primarily driven by the sustained success of its lead product cabozantinib (Cabo), which has demonstrated strong long-term data supporting its efficacy in renal cell carcinoma (RCC) while expanding its label in neuroendocrine tumors (NETs). The company’s strategic collaborations, particularly with Natera for the STELLAR-316 trial, signal a proactive approach to advancing its pipeline, enhancing the potential for future growth. Furthermore, the favorable outcomes reported in the STELLAR-303 trial for zanzalintinib's combination therapy bolster Exelixis's prospects in the competitive landscape of metastatic colorectal cancer (mCRC).
Bears say
Exelixis Inc faces multiple risks that contribute to a negative outlook on its stock, particularly regarding its primary product, Cabometyx (cabozantinib), which may experience significant market share erosion due to competition and potential generic entry. Additionally, the company's ongoing clinical programs, especially those involving zanzalintinib, have demonstrated disappointing efficacy results that fell short of investor expectations, raising concerns about future revenue generation. Overall, the combination of commercial risks, long-term dilution possibilities, and regulatory uncertainties underscores a cautious perspective on Exelixis's financial health and stock valuation.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares